Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in Breast Cancer Res

Retrieve available abstracts of 134 articles:
HTML format

Single Articles

    October 2021
  1. FUH KF, Shepherd RD, Withell JS, Kooistra BK, et al
    Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.
    Breast Cancer Res. 2021;23:97.
    PubMed     Abstract available

  2. CHEN X, Chen DG, Zhao Z, Balko JM, et al
    Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.
    Breast Cancer Res. 2021;23:96.
    PubMed     Abstract available

  3. HAZLETT J, Niemi V, Aiderus A, Powell K, et al
    Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2021;23:95.
    PubMed     Abstract available

    September 2021
  4. LIOU L, Kaptoge S, Dennis J, Shah M, et al
    Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
    Breast Cancer Res. 2021;23:94.
    PubMed     Abstract available

  5. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
    Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
    Breast Cancer Res. 2021;23:91.
    PubMed     Abstract available

  6. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
    Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
    Breast Cancer Res. 2021;23:93.
    PubMed     Abstract available

  7. ZARE A, Postovit LM, Githaka JM
    Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Breast Cancer Res. 2021;23:92.
    PubMed     Abstract available

  8. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
    A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Breast Cancer Res. 2021;23:90.
    PubMed     Abstract available

    August 2021
  9. ROMINE PE, Peterson LM, Kurland BF, Byrd DW, et al
    (18)F-fluorodeoxyglucose (FDG) PET or (18)F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.
    Breast Cancer Res. 2021;23:88.
    PubMed     Abstract available

  10. NEVEN P, Rugo HS, Tolaney SM, Iwata H, et al
    Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Breast Cancer Res. 2021;23:87.
    PubMed     Abstract available

  11. MORRA A, Escala-Garcia M, Beesley J, Keeman R, et al
    Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
    Breast Cancer Res. 2021;23:86.
    PubMed     Abstract available

  12. BRETT JO, Spring LM, Bardia A, Wander SA, et al
    ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Breast Cancer Res. 2021;23:85.
    PubMed     Abstract available

  13. FERRARO E, Drago JZ, Modi S
    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Breast Cancer Res. 2021;23:84.
    PubMed     Abstract available

  14. LAL JC, Townsend MG, Mehta AK, Oliwa M, et al
    Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Breast Cancer Res. 2021;23:83.
    PubMed     Abstract available

  15. GARAY JP, Smith R, Devlin K, Hollern DP, et al
    Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Breast Cancer Res. 2021;23:81.
    PubMed     Abstract available

  16. CHEW NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, et al
    Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Breast Cancer Res. 2021;23:82.
    PubMed     Abstract available

  17. RIBEIRO GUERRA M, Coignard J, Eon-Marchais S, Dondon MG, et al
    Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
    Breast Cancer Res. 2021;23:79.
    PubMed     Abstract available

  18. JONES GS, Hoadley KA, Olsson LT, Hamilton AM, et al
    Hepatocyte growth factor pathway expression in breast cancer by race and subtype.
    Breast Cancer Res. 2021;23:80.
    PubMed     Abstract available

    July 2021
  19. CHENG TD, Omilian AR, Yao S, Zhang W, et al
    Body fatness and breast cancer risk in relation to phosphorylated mTOR expression in a sample of predominately Black women.
    Breast Cancer Res. 2021;23:77.
    PubMed     Abstract available

  20. MOHAMMED S, Shamseddine AA, Newcomb B, Chavez RS, et al
    Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases.
    Breast Cancer Res. 2021;23:76.
    PubMed     Abstract available

  21. SCHAAFSMA E, Zhang B, Schaafsma M, Tong CY, et al
    Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.
    Breast Cancer Res. 2021;23:74.
    PubMed     Abstract available

  22. OTTOLINO-PERRY K, Shahid A, DeLuca S, Son V, et al
    Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial.
    Breast Cancer Res. 2021;23:72.
    PubMed     Abstract available

  23. YAGHJYAN L, Austin-Datta RJ, Oh H, Heng YJ, et al
    Associations of reproductive breast cancer risk factors with breast tissue composition.
    Breast Cancer Res. 2021;23:70.
    PubMed     Abstract available

    June 2021
  24. SAYED S, Fan S, Moloo Z, Wasike R, et al
    Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.
    Breast Cancer Res. 2021;23:68.
    PubMed     Abstract available

  25. THIES KA, Cole MW, Schafer RE, Spehar JM, et al
    The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Breast Cancer Res. 2021;23:65.
    PubMed     Abstract available

  26. CATTIN S, Fellay B, Calderoni A, Christinat A, et al
    Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis.
    Breast Cancer Res. 2021;23:64.
    PubMed     Abstract available

    May 2021
  27. HAN Y, Lv J, Yu C, Guo Y, et al
    Development and external validation of a breast cancer absolute risk prediction model in Chinese population.
    Breast Cancer Res. 2021;23:62.
    PubMed     Abstract available

  28. AL-ZAHRANI KN, Abou-Hamad J, Pascoal J, Labreche C, et al
    Correction to: AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer.
    Breast Cancer Res. 2021;23:60.

  29. PANJARIAN S, Madzo J, Keith K, Slater CM, et al
    Accelerated aging in normal breast tissue of women with breast cancer.
    Breast Cancer Res. 2021;23:58.
    PubMed     Abstract available

  30. JACQUEMETTON J, Kassem L, Poulard C, Dahmani A, et al
    Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Breast Cancer Res. 2021;23:57.
    PubMed     Abstract available

  31. DINCA SC, Greiner D, Weidenfeld K, Bond L, et al
    Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
    Breast Cancer Res. 2021;23:56.
    PubMed     Abstract available

  32. AL-ZAHRANI KN, Abou-Hamad J, Pascoal J, Labreche C, et al
    AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer.
    Breast Cancer Res. 2021;23:55.
    PubMed     Abstract available

  33. LAINE M, Fanning SW, Chang YF, Green B, et al
    Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Breast Cancer Res. 2021;23:54.
    PubMed     Abstract available

  34. ZHENG Y, Li B, Pan D, Cao J, et al
    Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    Breast Cancer Res. 2021;23:53.
    PubMed     Abstract available

    April 2021
  35. GU J, Polley EC, Denis M, Carter JM, et al
    Early assessment of shear wave elastography parameters foresees the response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Breast Cancer Res. 2021;23:52.
    PubMed     Abstract available

  36. CIABATTONI A, Gregucci F, Fastner G, Cavuto S, et al
    Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.
    Breast Cancer Res. 2021;23:50.

  37. GATTI G, Betts C, Rocha D, Nicola M, et al
    Correction to: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
    Breast Cancer Res. 2021;23:48.

  38. FORNILI M, Perduca V, Fournier A, Jerolon A, et al
    Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
    Breast Cancer Res. 2021;23:47.
    PubMed     Abstract available

  39. LIN L, Kuhn C, Ditsch N, Kolben T, et al
    Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs).
    Breast Cancer Res. 2021;23:45.
    PubMed     Abstract available

  40. CIABATTONI A, Gregucci F, Fastner G, Cavuto S, et al
    IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.
    Breast Cancer Res. 2021;23:46.
    PubMed     Abstract available

  41. WU AH, Franke AA, Wilkens LR, Tseng C, et al
    Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study.
    Breast Cancer Res. 2021;23:44.
    PubMed     Abstract available

    March 2021
  42. SANZ-MORENO A, Palomeras S, Pedersen K, Morancho B, et al
    RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Breast Cancer Res. 2021;23:42.
    PubMed     Abstract available

  43. GATTI G, Betts C, Rocha D, Nicola M, et al
    High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
    Breast Cancer Res. 2021;23:40.
    PubMed     Abstract available

  44. YU J, Qin B, Moyer AM, Sinnwell JP, et al
    Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Breast Cancer Res. 2021;23:41.

  45. DEMICHELE A, Cristofanilli M, Brufsky A, Liu X, et al
    Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    Breast Cancer Res. 2021;23:37.
    PubMed     Abstract available

  46. GALARDI F, De Luca F, Biagioni C, Migliaccio I, et al
    Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Breast Cancer Res. 2021;23:38.
    PubMed     Abstract available

  47. WU SY, Sharma S, Wu K, Tyagi A, et al
    Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
    Breast Cancer Res. 2021;23:35.
    PubMed     Abstract available

  48. FIGUEROA JD, Gierach GL, Duggan MA, Fan S, et al
    Risk factors for breast cancer development by tumor characteristics among women with benign breast disease.
    Breast Cancer Res. 2021;23:34.
    PubMed     Abstract available

  49. GRAESER M, Schrading S, Gluz O, Strobel K, et al
    Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
    Breast Cancer Res. 2021;23:36.
    PubMed     Abstract available

  50. MACPHERSON IR, He Y, Palmieri C
    Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
    Breast Cancer Res. 2021;23:33.
    PubMed     Abstract available

  51. DARRIGUES L, Pierga JY, Bernard-Tessier A, Bieche I, et al
    Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Breast Cancer Res. 2021;23:31.
    PubMed     Abstract available

  52. PAIRAWAN S, Zhao M, Yuca E, Annis A, et al
    First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
    Breast Cancer Res. 2021;23:29.
    PubMed     Abstract available

  53. STRINGER-REASOR EM, May JE, Olariu E, Caterinicchia V, et al
    An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    Breast Cancer Res. 2021;23:30.
    PubMed     Abstract available

    February 2021
  54. AINE M, Boyaci C, Hartman J, Hakkinen J, et al
    Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly.
    Breast Cancer Res. 2021;23:28.

  55. STENSTROM J, Hedenfalk I, Hagerling C
    Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Breast Cancer Res. 2021;23:27.
    PubMed     Abstract available

  56. KAMINSKA K, Akrap N, Staaf J, Alves CL, et al
    Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Breast Cancer Res. 2021;23:26.
    PubMed     Abstract available

  57. RAMIN C, Withrow DR, Davis Lynn BC, Gierach GL, et al
    Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Breast Cancer Res. 2021;23:24.
    PubMed     Abstract available

  58. PAL CHOUDHURY P, Brook MN, Hurson AN, Lee A, et al
    Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Breast Cancer Res. 2021;23:22.
    PubMed     Abstract available

  59. MOURON S, Manso L, Caleiras E, Rodriguez-Peralto JL, et al
    FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Breast Cancer Res. 2021;23:21.
    PubMed     Abstract available

  60. AINE M, Boyaci C, Hartman J, Hakkinen J, et al
    Molecular analyses of triple-negative breast cancer in the young and elderly.
    Breast Cancer Res. 2021;23:20.
    PubMed     Abstract available

  61. GILMORE N, Mohile S, Lei L, Culakova E, et al
    The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy.
    Breast Cancer Res. 2021;23:19.
    PubMed     Abstract available

  62. SHANG L, Hattori M, Fleming G, Jaskowiak N, et al
    Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.
    Breast Cancer Res. 2021;23:18.
    PubMed     Abstract available

  63. JOHANSSON ALV, Trewin CB, Fredriksson I, Reinertsen KV, et al
    In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
    Breast Cancer Res. 2021;23:17.
    PubMed     Abstract available

    January 2021
  64. ROHAN TE, Arthur R, Wang Y, Weinmann S, et al
    Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer.
    Breast Cancer Res. 2021;23:15.
    PubMed     Abstract available

  65. ROZENBLIT M, Mun S, Soulos P, Adelson K, et al
    Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Breast Cancer Res. 2021;23:14.
    PubMed     Abstract available

  66. ASPERGER H, Stamm N, Gierke B, Pawlak M, et al
    Correction to: Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
    Breast Cancer Res. 2021;23:13.

  67. CHEN C, Pan Y, Bai L, Chen H, et al
    MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer.
    Breast Cancer Res. 2021;23:12.
    PubMed     Abstract available

  68. JIAO X, Wang M, Zhang Z, Li Z, et al
    Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.
    Breast Cancer Res. 2021;23:11.
    PubMed     Abstract available

  69. ALHENC-GELAS M, Cabel L, Berger F, Delaloge S, et al
    Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
    Breast Cancer Res. 2021;23:9.
    PubMed     Abstract available

  70. SCHMID P, Sablin MP, Bergh J, Im SA, et al
    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
    Breast Cancer Res. 2021;23:8.
    PubMed     Abstract available

  71. SANCHEZ K, Kim I, Chun B, Pucilowska J, et al
    Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
    Breast Cancer Res. 2021;23:2.
    PubMed     Abstract available

  72. LIAO YM, Wang YH, Hung JT, Lin YJ, et al
    High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Breast Cancer Res. 2021;23:5.
    PubMed     Abstract available

  73. HOWARTH KD, Mirza T, Cooke SL, Chin SF, et al
    NRG1 fusions in breast cancer.
    Breast Cancer Res. 2021;23:3.
    PubMed     Abstract available

  74. SOBOTTKA B, Moch H, Varga Z
    Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer.
    Breast Cancer Res. 2021;23:4.
    PubMed     Abstract available

  75. PRIEDIGKEIT N, Ding K, Horne W, Kolls JK, et al
    Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
    Breast Cancer Res. 2021;23:1.
    PubMed     Abstract available

    December 2020
  76. LUNDGREN C, Bendahl PO, Ekholm M, Ferno M, et al
    Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Breast Cancer Res. 2020;22:140.
    PubMed     Abstract available

  77. SEREESONGSAENG N, McDowell SH, Burrows JF, Scott CJ, et al
    Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.
    Breast Cancer Res. 2020;22:139.
    PubMed     Abstract available

  78. WATT GP, Sung J, Morris EA, Buys SS, et al
    Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    Breast Cancer Res. 2020;22:138.
    PubMed     Abstract available

  79. ALHAREERI AA, Archer KJ, Fu H, Lyon DE, et al
    Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study.
    Breast Cancer Res. 2020;22:137.
    PubMed     Abstract available

  80. WAFAI R, Williams ED, de Souza E, Simpson PT, et al
    Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer-insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system.
    Breast Cancer Res. 2020;22:136.
    PubMed     Abstract available

  81. GHALEB A, Padellan M, Marchenko N
    Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Breast Cancer Res. 2020;22:133.
    PubMed     Abstract available

  82. FERNANDEZ SV, MacFarlane AW 4th, Jillab M, Arisi MF, et al
    Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Breast Cancer Res. 2020;22:134.
    PubMed     Abstract available

  83. FREDOLINI C, Pathak KV, Paris L, Chapple KM, et al
    Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
    Breast Cancer Res. 2020;22:135.
    PubMed     Abstract available

    November 2020
  84. LEONE JP, Emblem KE, Weitz M, Gelman RS, et al
    Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
    Breast Cancer Res. 2020;22:131.
    PubMed     Abstract available

  85. ZOELLER JJ, Vagodny A, Daniels VW, Taneja K, et al
    Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Breast Cancer Res. 2020;22:132.
    PubMed     Abstract available

  86. LEE KM, Lee H, Han D, Moon WK, et al
    Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.
    Breast Cancer Res. 2020;22:130.
    PubMed     Abstract available

  87. WANG SM, Pfeiffer RM, Gierach GL, Falk RT, et al
    Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
    Breast Cancer Res. 2020;22:129.
    PubMed     Abstract available

  88. JORDAN KR, Hall JK, Schedin T, Borakove M, et al
    Extracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach.
    Breast Cancer Res. 2020;22:128.
    PubMed     Abstract available

  89. BHATTARAI S, Saini G, Gogineni K, Aneja R, et al
    Quadruple-negative breast cancer: novel implications for a new disease.
    Breast Cancer Res. 2020;22:127.
    PubMed     Abstract available

  90. GIANNOUDIS A, Malki MI, Rudraraju B, Mohhamed H, et al
    Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Breast Cancer Res. 2020;22:126.
    PubMed     Abstract available

  91. BALCIOGLU O, Heinz RE, Freeman DW, Gates BL, et al
    CRIPTO antagonist ALK4(L75A)-Fc inhibits breast cancer cell plasticity and adaptation to stress.
    Breast Cancer Res. 2020;22:125.
    PubMed     Abstract available

  92. QUINTELA-FANDINO M, Holgado E, Manso L, Morales S, et al
    Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
    Breast Cancer Res. 2020;22:124.
    PubMed     Abstract available

  93. KIMBUNG S, Inasu M, Stalhammar T, Nodin B, et al
    CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
    Breast Cancer Res. 2020;22:123.
    PubMed     Abstract available

  94. DOAN TB, Cheung V, Clyne CD, Hilton HN, et al
    A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer.
    Breast Cancer Res. 2020;22:122.
    PubMed     Abstract available

  95. REDDY TP, Rosato RR, Li X, Moulder S, et al
    A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
    Breast Cancer Res. 2020;22:121.
    PubMed     Abstract available

  96. GARRIDO-CASTRO AC, Saura C, Barroso-Sousa R, Guo H, et al
    Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Breast Cancer Res. 2020;22:120.
    PubMed     Abstract available

    October 2020
  97. HAN S, Choi JY
    Prognostic value of (18)F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2020;22:119.
    PubMed     Abstract available

  98. CAIRAT M, Al Rahmoun M, Gunter MJ, Severi G, et al
    Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women.
    Breast Cancer Res. 2020;22:118.
    PubMed     Abstract available

  99. FRANCESCANGELI F, De Angelis ML, Zeuner A
    COVID-19: a potential driver of immune-mediated breast cancer recurrence?
    Breast Cancer Res. 2020;22:117.
    PubMed     Abstract available

  100. AQBI HF, Coleman C, Zarei M, Manjili SH, et al
    Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
    Breast Cancer Res. 2020;22:116.
    PubMed     Abstract available

  101. DI COSIMO S, Porcu L, Agbor-Tarh D, Cinieri S, et al
    Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
    Breast Cancer Res. 2020;22:115.
    PubMed     Abstract available

  102. HENG B, Bilgin AA, Lovejoy DB, Tan VX, et al
    Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.
    Breast Cancer Res. 2020;22:113.
    PubMed     Abstract available

  103. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
    Pubertal timing and breast cancer risk in the Sister Study cohort.
    Breast Cancer Res. 2020;22:112.
    PubMed     Abstract available

  104. O'SHAUGHNESSY J, Brezden-Masley C, Cazzaniga M, Dalvi T, et al
    Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    Breast Cancer Res. 2020;22:114.
    PubMed     Abstract available

  105. DE GREGORIO A, Haberle L, Fasching PA, Muller V, et al
    Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
    Breast Cancer Res. 2020;22:111.
    PubMed     Abstract available

  106. MONSON KR, Goldberg M, Wu HC, Santella RM, et al
    Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    Breast Cancer Res. 2020;22:109.
    PubMed     Abstract available

  107. DRUCKER A, Yoo BH, Khan IA, Choi D, et al
    Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Breast Cancer Res. 2020;22:110.
    PubMed     Abstract available

  108. TUAZON AMA, Lott P, Bohorquez M, Benavides J, et al
    Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
    Breast Cancer Res. 2020;22:108.
    PubMed     Abstract available

  109. FUMAGALLI C, Ranghiero A, Gandini S, Corso F, et al
    Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Breast Cancer Res. 2020;22:107.
    PubMed     Abstract available

  110. FALSTIE-JENSEN AM, Esen BO, Kjaersgaard A, Lorenzen EL, et al
    Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study.
    Breast Cancer Res. 2020;22:106.
    PubMed     Abstract available

  111. DURCKER A, Yoo BH, Khan IA, Choi D, et al
    Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Breast Cancer Res. 2020;22:105.
    PubMed     Abstract available

    September 2020
  112. WANG D, Xiao F, Feng Z, Li M, et al
    Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
    Breast Cancer Res. 2020;22:103.
    PubMed     Abstract available

  113. BRENTNALL AR, Warren R, Harkness EF, Astley SM, et al
    Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
    Breast Cancer Res. 2020;22:101.
    PubMed     Abstract available

  114. MORSING M, Kim J, Villadsen R, Goldhammer N, et al
    Fibroblasts direct differentiation of human breast epithelial progenitors.
    Breast Cancer Res. 2020;22:102.
    PubMed     Abstract available

  115. NIEHOFF NM, Keil AP, Jones RR, Fan S, et al
    Outdoor air pollution and terminal duct lobular involution of the normal breast.
    Breast Cancer Res. 2020;22:100.
    PubMed     Abstract available

  116. LEE ARGOV EJ, Acheampong T, Terry MB, Rodriguez CB, et al
    Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.
    Breast Cancer Res. 2020;22:99.
    PubMed     Abstract available

    August 2020
  117. GABRIELSON M, Azam S, Hardell E, Holm M, et al
    Hormonal determinants of mammographic density and density change.
    Breast Cancer Res. 2020;22:95.
    PubMed     Abstract available

  118. KUROZUMI S, Alsaleem M, Monteiro CJ, Bhardwaj K, et al
    Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Breast Cancer Res. 2020;22:85.
    PubMed     Abstract available

    July 2020
  119. KANG T, Yau C, Wong CK, Sanborn JZ, et al
    A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
    Breast Cancer Res. 2020;22:81.
    PubMed     Abstract available

  120. RUUD KF, Hiscox WC, Yu I, Chen RK, et al
    Distinct phenotypes of cancer cells on tissue matrix gel.
    Breast Cancer Res. 2020;22:82.
    PubMed     Abstract available

  121. SINGH M, Zhou X, Chen X, Santos GS, et al
    Identification and targeting of selective vulnerability rendered by tamoxifen resistance.
    Breast Cancer Res. 2020;22:80.
    PubMed     Abstract available

    June 2020
  122. ABDOU Y, Attwood K, Cheng TD, Yao S, et al
    Racial differences in CD8(+) T cell infiltration in breast tumors from Black and White women.
    Breast Cancer Res. 2020;22:62.
    PubMed     Abstract available

  123. PAUL R, Luo M, Mo X, Lu J, et al
    FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
    Breast Cancer Res. 2020;22:59.
    PubMed     Abstract available

    May 2020
  124. CHOOTIPONGCHAIVAT S, van Ravesteyn NT, Li X, Huang H, et al
    Modeling the natural history of ductal carcinoma in situ based on population data.
    Breast Cancer Res. 2020;22:53.
    PubMed     Abstract available

  125. REDDY TP, Choi DS, Anselme AC, Qian W, et al
    Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
    Breast Cancer Res. 2020;22:48.
    PubMed     Abstract available

  126. SIRISENA N, Biswas K, Sullivan T, Stauffer S, et al
    Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.
    Breast Cancer Res. 2020;22:43.
    PubMed     Abstract available

  127. BURKHOLDER A, Akrobetu D, Pandiri AR, Ton K, et al
    Investigation of the adolescent female breast transcriptome and the impact of obesity.
    Breast Cancer Res. 2020;22:44.
    PubMed     Abstract available

    March 2020
  128. KIM M, Chung YR, Kim HJ, Woo JW, et al
    Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Breast Cancer Res. 2020;22:32.
    PubMed     Abstract available

  129. TANK A, Peterson HM, Pera V, Tabassum S, et al
    Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
    Breast Cancer Res. 2020;22:29.
    PubMed     Abstract available

  130. LI M, Pan M, You C, Zhao F, et al
    MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
    Breast Cancer Res. 2020;22:26.
    PubMed     Abstract available

    February 2020
  131. LLANOS AAM, Lin Y, Chen W, Yao S, et al
    Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype.
    Breast Cancer Res. 2020;22:18.
    PubMed     Abstract available

    January 2020
  132. OCANA A, Amir E, Pandiella A
    HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
    Breast Cancer Res. 2020;22:15.
    PubMed     Abstract available

  133. JABER MI, Song B, Taylor C, Vaske CJ, et al
    A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Breast Cancer Res. 2020;22:12.
    PubMed     Abstract available

  134. YOOSUF N, Navarro JF, Salmen F, Stahl PL, et al
    Identification and transfer of spatial transcriptomics signatures for cancer diagnosis.
    Breast Cancer Res. 2020;22:6.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.